Clinical Trial Update: CT011 Autologous CAR-T Cells in Patients With Hepatocellular Carcinoma at Risk of Recurrence After Surgical Resection [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating CT011 autologous CAR-T cells for hepatocellular carcinoma in patients at risk of recurrence after surgical resection; recruitm…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• CT011 Autologous CAR-T Cells (CT011 CAR-T cell therapy)

Snippet

Sponsor: CARsgen Therapeutics Co., Ltd. | Conditions: HCC | Phase 1 | Status: RECRUITING